Severe cardiovascular system involvement in a patient with Marfan’s syndrome
Abstract
The given clinical case of a 14-year-old child with Marfan’s syndrome demonstrates the early severe cardiovascular system diseases, such as dilated cardiomyopathy and aortic root dilatation, that required surgical treatment when he was 9 years old, and grades 2 and 3 insufficiency of the mitral and aortic valves, respectively. The paper presents the modern view of the involvement of the heart and vessels in Marfan’s syndrome (cardiomyopathy as a new sign of the disease, arterial dissection). It shows new possibilities for treating cardiovascular disorders in children with this disease, such as pathogenetic therapy with losartan, anti-transforming growth factor-β antibodies.
About the Authors
O. S. GroznovaRussian Federation
E. P. Kalachanova
Russian Federation
I. V. Leontyeva
Russian Federation
P. E. Rzhevskaya
Russian Federation
References
1. Harris C.G., Croce B., Tian D.H. Marfan syndrome. Ann Cardiothorac Surg 2014; 3: 4: 437.
2. McKusick V. The defect in Marfan syndrome. Nature 1991; 352: 279—281.
3. Orphanet Report Series. Prevalence of rare diseases: Bibliographic data. 2014; 1. http://www.orpha.net/consor/cgi-bin/ Disease_Search.
4. Семячкина А.Н. Клинический полиморфизм наследственных болезней соединительной ткани у детей: Автореф. дисс. … д-ра мед. наук. М 1995; 35. (Semyachkina А.N. Clinical polymorphism of hereditary connective tissue diseases in children: Аvtoref. dis. … d-ra med. nauk. Moscow 1995; 35.)
5. Romaniello F., Mazzaglia D., Pellegrino A. et al. Aortopathy in Marfan syndrome: an update. Cardiovasc Pathol 2014; 23: 5: 261—266.
6. Eggebrecht H. Diagnosis and treatment of aortic diseases : new guidelines of the European Society of Cardiology 2014. Herz 2014; 39: 8: 931—940.
7. Cook J.R., Carta L., Bénard L. et al. Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. J Clin Invest 2014; 124: 3: 1329—1339.
8. Hoffmann B.A., Rybczynski M., Rostock T. et al. Prospective risk stratification of sudden cardiac death in Marfan’s syndrome. Int J Cardiol 2013; 167: 6: 2539—2545.
9. Sandor G.G., Alghamdi M.H., Raffin L.A. et al. A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes. Int J Cardiol 2015; 179: 470—475.
10. Franken R., Radonic T., den Hartog A.W. et al. The revised role of TGF-β in aortic aneurysms in Marfan syndrome. COMPARE study group. Neth Heart J 2015; 23: 2: 116—121.
11. Pyeritz R.E. What is the optimal medical therapy for Marfan syndrome? J Pediat 2014; 165: 5: 889—890.
12. Perrino C., Schiattarella G.G., Bottino R. et al. Novel pharmacological strategies for aortic dilation in Marfan syndrome: from mouse models to human patients. G Ital Cardiol (Rome) 2014; 15: 7—8: 408—417.
Review
For citations:
Groznova O.S., Kalachanova E.P., Leontyeva I.V., Rzhevskaya P.E. Severe cardiovascular system involvement in a patient with Marfan’s syndrome. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2015;60(2):95-99.
Email this article 